Skip to main content
Journal cover image

Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer.

Publication ,  Journal Article
Raman, V; Jawitz, OK; Yang, C-FJ; Voigt, SL; Tong, BC; D'Amico, TA; Harpole, DH
Published in: J Thorac Oncol
December 2019

INTRODUCTION: There are limited small, single-institution observational studies examining the role of surgery in large cell neuroendocrine cancer (LCNEC). We investigated the outcomes of surgery for stage I to IIIA LCNEC by using the National Cancer Database. METHODS: Patients with stage I to IIIA LCNEC were identified in the National Cancer Database (2004-2015) and grouped by treatment: definitive chemoradiation versus surgery. Overall survival, by stage, was the primary outcome. Outcomes of surgical patients were also compared with those of patients with SCLC or other non-small cell histotypes. RESULTS: A total of 6092 patients met the criteria: 96%, 94%, 75%, and 62% of patients received an operation for stage I, II, IIIA, and cN2 disease, respectively. Complete resection was achieved in at least 85% of patients. The 5-year survival rates for patients undergoing an operation for stage I and II LCNEC were 50% and 45%, respectively. Surgical patients with stage IIIA and N2 disease had 36% and 32% 5-year survival rates, respectively. When compared with stereotactic body radiation in stage I disease and chemoradiation in patients with stage II to IIIA disease, surgery was associated with a survival benefit. Patients with LCNEC who underwent an operation generally experienced worse survival by stage than did those with adenocarcinoma but experienced improved survival compared with patients with SCLC. Perioperative chemotherapy was associated with improved survival for pathologic stage II to IIIA disease. CONCLUSIONS: Surgery is associated with reasonable outcomes for stage I to IIA LCNEC, although survival is generally worse than for adenocarcinoma. Surgery should be offered to medically fit patients with both early and locally advanced LCNEC, with guideline-concordant induction or adjuvant therapy.

Duke Scholars

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

December 2019

Volume

14

Issue

12

Start / End Page

2143 / 2151

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Humans
  • Female
  • Carcinoma, Neuroendocrine
  • Carcinoma, Large Cell
  • Aged
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Raman, V., Jawitz, O. K., Yang, C.-F., Voigt, S. L., Tong, B. C., D’Amico, T. A., & Harpole, D. H. (2019). Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol, 14(12), 2143–2151. https://doi.org/10.1016/j.jtho.2019.09.005
Raman, Vignesh, Oliver K. Jawitz, Chi-Fu J. Yang, Soraya L. Voigt, Betty C. Tong, Thomas A. D’Amico, and David H. Harpole. “Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer.J Thorac Oncol 14, no. 12 (December 2019): 2143–51. https://doi.org/10.1016/j.jtho.2019.09.005.
Raman V, Jawitz OK, Yang C-FJ, Voigt SL, Tong BC, D’Amico TA, et al. Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol. 2019 Dec;14(12):2143–51.
Raman, Vignesh, et al. “Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer.J Thorac Oncol, vol. 14, no. 12, Dec. 2019, pp. 2143–51. Pubmed, doi:10.1016/j.jtho.2019.09.005.
Raman V, Jawitz OK, Yang C-FJ, Voigt SL, Tong BC, D’Amico TA, Harpole DH. Outcomes for Surgery in Large Cell Lung Neuroendocrine Cancer. J Thorac Oncol. 2019 Dec;14(12):2143–2151.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

December 2019

Volume

14

Issue

12

Start / End Page

2143 / 2151

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Humans
  • Female
  • Carcinoma, Neuroendocrine
  • Carcinoma, Large Cell
  • Aged
  • 3211 Oncology and carcinogenesis